SiPhox Health is best for quick, repeatable at-home panels with an AI read. Everlywell is best for a wide catalog of one-off at-home tests plus monthly membership credits. AMORTAL is neither: it decides whether a test will change a decision, whether an at-home result is enough or needs confirming, and turns whichever you use into one ranked next action and an outcome loop.
SiPhox Health and Everlywell are two ways to test at home — and they’re built on different bets. SiPhox leans into quick, repeatable self-collected panels you can run on a schedule, with an AI assistant to read the results back to you. Everlywell leans into a broad catalog of mail-in at-home tests plus a membership that hands you a credit a month and discounts on more.
Both answer “can I test this from home?” well, in their own way. Neither is built to answer the harder questions that come next: “is this test even worth doing, is an at-home result enough or should I confirm it, and what should I actually change?” That’s the gap this page is about — and where AMORTAL fits, on top of whichever one you pick. It’s educational, not medical advice.
vs
+
Use SiPhox or Everlywell to test at home. Use AMORTAL to decide whether a test will change a decision, when an at-home result is enough, and what to do next.
The short version: who each is for
Two of these collect data at home in different shapes; the third decides what to do with whichever you have. Here’s the honest split.
Which one fits which job
SiPhox HealthBest for at-home convenienceQuick, self-collected at-home panels you can repeat on a schedule (SiPhox advertises 50+ biomarkers and results in 7–10 days; verify current), with an AI assistant called Sai to talk through results. Strongest when you want fast, repeatable tracking of a few markers without a lab visit.
EverlywellBest for at-home test varietyA broad catalog of mail-in at-home tests, plus the Everlywell+ membership (advertised at $39/month) that includes a credit a month and member discounts on more tests and virtual consults. Strongest when you want one-off tests across many areas with occasional savings.
AMORTALBest for deciding what to do nextNot a lab. A longitudinal decision layer that reads whatever results you already have — from either provider — and decides whether a test was worth doing, whether an at-home result is enough, and returns one ranked next action and an outcome loop. Including when to do nothing.
This isn't an "A beats B." SiPhox and Everlywell answer can I test this at home in different shapes; AMORTAL answers whether the test changes anything. The strongest setup is one of them plus AMORTAL.
SiPhox vs Everlywell vs AMORTAL, at a glance
Tap between the three to see what each is actually responsible for.
What each one owns
Same goal — better decisions from at-home tests — split into two ways to collect data and one decision layer.
SiPhox — quick repeat at-home panels
An at-home testing membership: self-collected samples (no lab visit), a panel SiPhox advertises at 50+ biomarkers with results in 7–10 days, personalized supplement and lifestyle recommendations, and an AI assistant called Sai. Built for repeat tracking on your own cadence.
You want fast, repeatable at-home tracking of a few markers with an AI read. Verify the current biomarker count, results window and pricing before buying.
Everlywell — the broad at-home catalog
A wide catalog of mail-in at-home tests across many health areas, plus the Everlywell+ membership (advertised at $39/month) that includes one credit a month and member discounts on additional tests and virtual consults. Built for occasional, varied testing.
You want one-off tests across many areas with monthly credits and occasional savings. Verify the current price, what a credit covers and the catalog before buying.
AMORTAL — the decision layer
Not a lab. It takes either provider's results, normalises them into a memory, and decides whether a test was worth doing, whether an at-home reading is enough or warrants confirming, and what one next action to take — with restraint built in.
You already have results and the real question is "what now?" — whether to act, whether to confirm, what to watch, and when a retest is actually worth it.
AMORTAL has no direct integration with either — you bring the data in by upload or manual entry.
The comparison, row by row
| Dimension | SiPhox Health | Everlywell | AMORTAL |
|---|---|---|---|
| Best use case | Quick repeat at-home tracking | Broad at-home test catalog | Deciding what the data should change |
| Collection method | Self-collected at-home sample, no lab visit (advertised) | Mail-in at-home self-collection kits (advertised) | No draws — works from results you have |
| Lab partner / processing | CLIA-certified lab processing (advertised) | CLIA-certified partner labs (advertised) | Lab-agnostic; vendor-neutral |
| Biomarker breadth | Repeatable panel (advertises 50+; verify) | Broad catalog (advertises up to 288 unique; verify) | Doesn’t test; reads whatever you bring |
| Wearable integration | Not the core product | Not the core product | Connects labs to Oura / Whoop / Apple Watch |
| Upload existing labs | Its own panels | Its own test catalog | Yes — bring either provider’s results in |
| AI / chat | Sai, an AI assistant (advertised) | Virtual consults, not an AI chat (advertised) | Auditable Decision Contract, not a chat |
| Clinician review | Personalized recommendations + Sai (advertised) | Physician-ordered; optional virtual consults (advertised) | Clinician-compatible questions; not a clinician |
| Action plan depth | Supplement + lifestyle recommendations (advertised) | Per-test guidance + consults (advertised) | One ranked next best action, plus restraint |
| Retesting cadence | Built for repeat tracking (monthly/quarterly) | One credit per month / one-off tests | Tells you when not to retest yet |
| Result trend tracking | Trends across SiPhox panels | Results in the Everlywell app | Longitudinal memory across providers and time |
| Abnormal-result handling | Flags + recommendations (advertised) | Physician-ordered; abnormal flags (advertised) | Safety-gated; routes urgent flags to a clinician |
| Cost model | Membership (verify current pricing) | Everlywell+ ~$39/mo (advertised; verify) | Decision layer — founding membership |
| Where AMORTAL fits | Repeat at-home panels in | Broad at-home catalog in | → ranked decision, watchlist, outcome loop out |
Provider rows describe what each company publicly advertises as of June 2026 — pricing, credits, marker counts and included features change often, so confirm current details on each provider's own pages before buying. Sources are at the foot of this page.
Which one fits what you actually want
| What you want | Reach for |
|---|---|
| Quick, repeatable at-home tracking of a few markers | SiPhox Health |
| An AI to read my at-home results back to me | SiPhox Health |
| A wide catalog of one-off at-home tests across many areas | Everlywell |
| A monthly membership credit toward at-home tests | Everlywell |
| I already have results — tell me what to do next | AMORTAL |
| To know whether a test is even worth doing | AMORTAL |
| Whether an at-home result is enough or needs a confirmatory draw | AMORTAL |
| A clinician-ready question, not a treatment directive | AMORTAL |
| To track whether a protocol actually worked | AMORTAL |
| To avoid over-reacting to one borderline number | AMORTAL |
Where AMORTAL fits — whichever you pick
The model is the same regardless of which option you choose: let the provider do the testing, then run the result through a decision process instead of a dashboard.
- Bring the result in. Upload your SiPhox or Everlywell report, or enter the key markers — there's no direct integration, so you carry the data over.
- Normalise into memory. AMORTAL files each biomarker into a longitudinal record, not a one-off screen.
- Connect the context. Results are linked to your goals, symptoms, wearables, medications and constraints.
- Activate the standards. The guidelines and decision rules that actually apply to your situation switch on.
- Produce a Decision Contract. One change at a time, with the expected signal and the window written down in advance.
- Rank one Next Best Action. Not ten. The single highest-value move — which may be "confirm this first" or "do nothing yet."
- Set the watchlist. Markers worth re-checking get an expected direction and a recheck window.
- Close the loop. When the next panel or outcome signal arrives, AMORTAL checks whether the action worked — and keeps or discards it.
A decision loop, end to end
Here’s the same flow on a single example — illustrative numbers only, not a target or a reference range.
From an at-home result to a tracked outcome
Your SiPhox or Everlywell panel returns a borderline-high marker (say, a fasting result in a range your clinician flags as worth attention). On a dashboard — or in an AI chat reply — that's a red number and a vague nudge.
AMORTAL files it next to your prior results, your goals, your medications and your wearable trends — read as a trajectory, not a single dot.
First question: is one at-home reading enough to act on, or does a borderline result warrant a confirmatory venous draw? One lever, with the expected signal and the window written down before anything changes.
Framed as a clinician-ready question — "given one borderline at-home reading, is a confirmatory draw the right first step before changing anything?" — not a treatment directive AMORTAL has no authority to give.
The marker goes on watch with an expected direction and a recheck window — so you retest when it's informative, not on a guess or a subscription date.
At the next reading, AMORTAL checks: did it confirm and move as expected? If yes, the change earns its place. If not, it's dropped — no story told over noise.
AMORTAL doesn't diagnose and isn't a substitute for your clinician — anything urgent goes to a professional, now.
SiPhox or Everlywell — which fits you?
If you’re choosing between the two, this narrows it. Whichever you land on, AMORTAL sits on top of it and adds the restraint.
SiPhox, Everlywell, or it depends?
What's your testing pattern?
What matters more right now?
Quick, repeatable at-home tracking with an AI read is SiPhox's strength. Verify the current panel, results window and price, run the test, then bring the results into AMORTAL — which flags when an at-home result is enough versus when it's worth confirming, and ranks what to actually do.
A broad at-home catalog with monthly credits fits occasional, varied testing. Verify what a credit covers and the current price, then use AMORTAL to decide which test is actually worth doing and turn the result into one auditable, outcome-tracked decision instead of a one-off readout.
Where each is strongest — and where it isn’t
In fairness to all three:
- SiPhox is strongest when you want fast, repeatable at-home tracking of a few markers with an AI read — and less ideal if your bottleneck is deciding what a result means or whether one reading is enough to act on.
- Everlywell is strongest when you want a wide catalog of one-off at-home tests plus monthly credits and occasional savings — and less ideal if you mainly need to repeat-track a few markers cheaply or want one integrated read across them.
- Verify before you buy. Prices, credits, biomarker claims, promotions and included features change for both — confirm the current details on each provider’s own pages.
- Convenience is a beginning, not an answer. Some results will need a clinician or a confirmatory venous draw; AMORTAL should never be read as a diagnosis, whichever provider produced the number.
Bring your results into a decision, not a dashboard
AMORTAL doesn’t need to be where you buy your tests. The stronger model is to let a provider like SiPhox or Everlywell do the testing, then use AMORTAL as the longitudinal decision system around those results. Upload the report, or enter the markers that matter. AMORTAL turns the result into memory, evaluates whether the test was even worth doing and whether one at-home reading is enough, ranks the next best action, sets a watchlist for the signals to expect, and later checks whether the action actually worked.
Already have results from SiPhox or Everlywell? Bring them into AMORTAL and ask the only question that matters: “What should I do next?”
Sources
Provider claims describe what each company publicly advertised when this page was last fact-checked (26 June 2026). Pricing, credits, marker counts and included features are volatile — verify on the official pages before purchase.
SiPhox Health — at-home testing claims, biomarker count, results window, Sai AI and pricing.
SiPhox Health — how it works: self-collection method and turnaround.
Everlywell+ — monthly at-home lab testing membership: price, monthly credit and member discounts.
Everlywell — membership detail: what's included, credits and catalog breadth.
Educational only — this is not medical advice or a diagnosis. Talk to a licensed clinician about your own numbers, targets, and any treatment decisions.
Frequently asked
SiPhox vs Everlywell — which should I choose?
It depends on your testing pattern. SiPhox is strongest for quick, repeatable at-home panels you run on a schedule, with an AI assistant to talk through the results. Everlywell is strongest as a broad catalog of one-off at-home tests plus a membership that gives you a credit a month and member discounts. Both publish their own pricing, credits and biomarker claims, which change often — verify the current details before buying. Whichever you pick, AMORTAL works on top of the results.
Can AMORTAL work with results from either SiPhox or Everlywell?
Yes. AMORTAL is lab-agnostic and works from results you already have — you bring them in by uploading the report or entering key markers (there's no direct integration with either). It normalises the biomarkers into a longitudinal memory, connects them to your goals, wearables and protocols, and returns one ranked next action rather than another dashboard. The provider you chose stays your data source; AMORTAL is the decision layer.
Does AMORTAL replace SiPhox or Everlywell?
No. They do a different job. SiPhox and Everlywell collect and report at-home test data; AMORTAL decides what that data should change, what to ignore, what to watch, when to retest, and whether an at-home result is even enough to act on. Most people keep their provider for the testing and use AMORTAL to turn each result into an auditable decision and an outcome loop.
SiPhox has an AI assistant (Sai) — how is AMORTAL different?
An AI assistant answers questions in the moment. AMORTAL produces a Decision Contract: it writes down one change, the single signal you'd expect it to move, and the window to watch — in advance — then checks later whether it actually worked. It's auditable and outcome-tracked rather than conversational, and it's deliberately built to recommend doing nothing, or confirming a result, when that's the right call.
Is an at-home result enough, or should I confirm it with a venous draw?
Sometimes an at-home reading is sufficient, and sometimes a single borderline or surprising result warrants a confirmatory venous draw or a clinician before you act. AMORTAL doesn't run the test or make the call for you — it weighs whether the result would actually change a decision, flags when one reading isn't enough to act on, and frames the next step as a clinician-ready question. Anything urgent or critical goes to a clinician now.
Are more biomarkers or more at-home tests always better — and when should I retest?
Not automatically. A broad catalog and big panels are useful, but more markers also mean more borderline results that tempt over-reaction, and at-home convenience makes it easy to test more often than is informative. AMORTAL evaluates whether a marker actually changes a realistic decision and sets an expected window per marker, so you retest when it's informative rather than on a renewal date — and don't mistake normal variation for a result.